Search

Displaying results 8381 - 8390 of 10000 in total
  1. Pathway

    Cardiolipin Biosynthesis CL(20:2(11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0256169
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  2. Pathway

    Cardiolipin Biosynthesis CL(20:3(11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z)/20:4(5Z,8Z,11Z,14Z))

    smpdb.ca/view/SMP0256333
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  3. Pathway

    Cardiolipin Biosynthesis CL(20:3(11Z,14Z,17Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:3(11Z,14Z,17Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0256346
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  4. Pathway

    Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:2(11Z,14Z)/20:3(11Z,14Z,17Z))

    smpdb.ca/view/SMP0287258
    Metabolic

    Cardiolipin (CL) is an important component of the inner mitochondrial membrane where it constitutes about 20% of the total lipid composition.

    Drugs: NADH · Cytidine-5'-Triphosphate · sn-glycerol 3-phosphate · Pyrophosphoric acid · Dihydroxyacetone phosphate
  5. Drug

    Oxyphenisatin acetate

    go.drugbank.com/drugs/DB14627
    ApprovedWithdrawn

    The FDA withdrew its approval for the use of oxyphenisatin acetate due to safety reasons.[L43942]

  6. Target

    17-beta-hydroxysteroid dehydrogenase type 2

    go.drugbank.com/bio_entities/BE0000006
    TargetEnzymeHumans

    Also has 20-alpha-HSD activity

    Synonyms: 20-alpha-HSD, 20 alpha-hydroxysteroid dehydrogenaseFunction: 17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase [NAD(P)+] activity
  7. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.

  8. Target

    L-xylulose reductase

    go.drugbank.com/bio_entities/BE0000869
    TargetHumans

    Catalyzes the NADPH-dependent reduction of several pentoses, tetroses, trioses, alpha-dicarbonyl compounds and L-xylulose (PubMed:11882650, PubMed:19337691, PubMed:40737316). Can use both NAD and NADP as cosubstrate but shows higher acti...

    Synonyms: Short chain dehydrogenase/reductase family 20C member 1
  9. Drug

    Zanidatamab

    go.drugbank.com/drugs/DB15471
    ApprovedInvestigational

    [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]

  10. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    In April 2018, the U.S. … Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies [A32865].